SQZ Biotech
NEWS
SQZ Biotech was acquired by STEMCELL Technologies in February 2024.
“We are thrilled to have the support of both our new and long-standing investors who believe in SQZ and our potential to create impactful therapies for patients,” said Teri Loxam, SQZ’s chief financial officer.
It was another busy week for clinical trial updates. Here’s a look.
Armon Sharei, chief executive officer of SQZ Biotech, said 2020 is going to be an exciting year for the company as it anticipates having clinical data available from its first trial by the end of this year.
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
Biopharma companies strengthen their senior leadership teams and boards of directors.
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
SQZ Biotech is on a roll. Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, the company is now expanding its footprint in Watertown, Mass.
JOBS
IN THE PRESS